DOCSLIB.ORG

RMP Buscopan Part 0 Preliminary Section

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RMP Buscopan Part 0 Preliminary Section EU RISK MANAGEMENT PLAN FOR HYOSCINE BUTYLBROMIDE PRELIMINARY SECTION Active substance(s) (INN or common name) Hyoscine butylbromide Belladonna alkaloids, semisynthetic, quarternary Pharmaco-therapeutic group (ATC Code) ammonium compounds (ATC code A03BB01) Name of Marketing Authorization Holder or Applicant Boehringer Ingelheim Limited Medicinal product(s) to which this RMP refers Hyoscine butylbromide (BUSCOPAN) (tablet and ampoule) Product(s) concerned (brand name(s)) BUSCOPAN ® (tablet and ampoule) Data lock point (DLP) for current Risk Management Plan 01-JUN-2016 (RMP) Version number of the current RMP Version 2.1_CA Date of final sign-off Property of the Sanofi group - strictly confidential Page 1 QSD-010763 Version 4.0 RISK MANAGEMENT PLAN - Preliminary Section FINAL DLP:01-JUN-2016 Product Code - Hyoscine butylbromide Version 2.1_CA Table 1 - RMP version to be assessed as part of this application RMP Version number Version 2.1_CA Data lock point for this RMP 01-JUN-2016 Date of final sign off Rationale for submitting an updated RMP Not applicable Summary of significant changes in this RMP Safety concerns: The important identified risk “Tachycardia in patients with cardiac risk factors (parenteral formulation)” was added. RMP: Risk Management Plan. Table 2 - Other RMP versions under evaluation RMP Version number Submitted on Submitted within Not applicable - - RMP: Risk Management Plan. Table 3 - Details of the currently approved RMP Version number 2.0 Approved with procedure - Date of approval (opinion date) - RMP: Risk Management Plan. Table 4 - QPPV name and signature QPPV name Dr. Sabine Jeck-Thole QPPV signature Electronic signature on file QPPV: Qualified Person for Pharmacovigilance. Property of the Sanofi group - strictly confidential Page 2 QSD-010763 Version 4.0 RISK MANAGEMENT PLAN - Preliminary Section FINAL DLP:01-JUN-2016 Product Code - Hyoscine butylbromide Version 2.1_CA TABLE OF CONTENT Property of the Sanofi group - strictly confidential Page 3 QSD-010763 Version 4.0 RISK MANAGEMENT PLAN - Preliminary Section FINAL DLP:01-JUN-2016 Product Code - Hyoscine butylbromide Version 2.1_CA LIST OF TABLES Table 1 - RMP version to be assessed as part of this application .................................................................. 2 Table 2 - Other RMP versions under evaluation ............................................................................................. 2 Table 3 - Details of the currently approved RMP ............................................................................................ 2 Table 4 - QPPV name and signature .............................................................................................................. 2 Table 5 - Overview of the RMP Parts and Modules in the current RMP ......................................................... 6 Property of the Sanofi group - strictly confidential Page 4 QSD-010763 Version 4.0 RISK MANAGEMENT PLAN - Preliminary Section FINAL DLP:01-JUN-2016 Product Code - Hyoscine butylbromide Version 2.1_CA ABBREVIATIONS ATC: Anatomical Therapeutic Chemical DLP: Data Lock Point INN: International Nonproprietary Name QPPV: Qualified Person for Pharmacovigilance RMP: Risk Management Plan Property of the Sanofi group - strictly confidential Page 5 QSD-010763 Version 4.0 RISK MANAGEMENT PLAN - Preliminary Section FINAL DLP:01-JUN-2016 Product Code - Hyoscine butylbromide Version 2.1_CA Table 5 - Overview of the RMP Parts and Modules in the current RMP Date of Rationale for update Module version PART MODULE or ANNEX approval number (opinion date) In the context of GVP V Part I – Product(s) revision 2, use of the 2.1_CA Not applicable overview corresponding EU-RMP template. In the context of GVP V revision 2, use of the Part II - Safety SI - Epidemiology of the 2.1_CA Not applicable specification indication(s) and target population(s) corresponding EU-RMP template. In the context of GVP V revision 2, use of the SII - Non-clinical part of the safety 2.1_CA Not applicable specification corresponding EU-RMP template. In the context of GVP V revision 2, use of the SIII - Clinical trial exposure 2.1_CA Not applicable corresponding EU-RMP template. In the context of GVP V revision 2, use of the SIV - Populations not studied in 2.1_CA Not applicable clinical trials corresponding EU-RMP template. In the context of GVP V revision 2, use of the SV - Post-authorization experience 2.1_CA Not applicable corresponding EU-RMP template. In the context of GVP V revision 2, use of the SVI - Additional EU requirements 2.1_CA Not applicable for the safety specification corresponding EU-RMP template. In the context of GVP V revision 2, use of the SVII - Identified and potential risks 2.1_CA Not applicable corresponding EU-RMP template. In the context of GVP V revision 2, use of the SVIII - Summary of the safety 2.1_CA Not applicable concerns corresponding EU-RMP template. Property of the Sanofi group - strictly confidential Page 6 QSD-010763 Version 4.0 RISK MANAGEMENT PLAN - Preliminary Section FINAL DLP:01-JUN-2016 Product Code - Hyoscine butylbromide Version 2.1_CA Part III - In the context of GVP V Pharmacovigilance plan revision 2, use of the (including post- 2.1_CA Not applicable corresponding EU-RMP authorization safety studies) template. Part IV - Plans for post- In the context of GVP V authorization efficacy revision 2, use of the 2.1_CA Not applicable studies corresponding EU-RMP template. Part V - Risk In the context of GVP V minimization measures revision 2, use of the (including evaluation of 2.1_CA Not applicable corresponding EU-RMP effectiveness of risk minimization activities) template. Part VI - Summary of In the context of GVP V the risk management plan revision 2, use of the 2.1_CA Not applicable corresponding EU-RMP template. Part VII - Annexes Annex 1 – Eudravigilance Not applicable Not applicable Not applicable Interface Annex 2 – Tabulated summary of In the context of GVP V revision 2, use of the planned, on-going and completed 2.1_CA Not applicable studies in the pharmacovigilance corresponding EU-RMP plan template. Annex 3 – Protocols for proposed, on-going, and completed Not applicable Not applicable Not applicable studies in the pharmacovigilance plan Annex 4 – Specific adverse event Not applicable Not applicable Not applicable follow-up forms Annex 5 – Protocols for proposed Not applicable Not applicable Not applicable and on-going studies in Part IV Annex 6 – Details of proposed Not applicable Not applicable Not applicable additional risk minimization activities In the context of GVP V revision 2, use of the Annex 7 – Other supporting data 2.1_CA Not applicable (including referenced material) corresponding EU-RMP template. In the context of GVP V Annex 8 - Summary of changes revision 2, use of the to the risk management plan over 2.1_CA Not applicable time corresponding EU-RMP template. Property of the Sanofi group - strictly confidential Page 7 QSD-010763 Version 4.0 RISK MANAGEMENT PLAN - PART I PRODUCT(S) OVERVIEW Active substance(s) (INN or common name) Hyoscine butylbromide Product(s) concerned (brand name(s)) BUSCOPAN ® tablet and ampoule) Name of Marketing Authorization Holder or Applicant Boehringer Ingelheim Limited Data lock point (DLP) for this module 01-JUN-2016 Version number of Risk Management Plan (RMP) when this Version 2.1_CA module was last updated Property of the Sanofi group - strictly confidential Page 1 QSD-010763 Version 4.0 RISK MANAGEMENT PLAN - PART I FINAL DLP:01-JUN-2016 Product Code - Hyoscine butylbromide Version 2.1_CA TABLE OF CONTENTS PRODUCT(S) OVERVIEW.............................................................................................................................. 1 TABLE OF CONTENTS .................................................................................................................................. 2 LIST OF TABLES ........................................................................................................................................... 3 ABBREVIATIONS ........................................................................................................................................... 4 REFERENCES ................................................................................................................................................ 9 Property of the Sanofi group - strictly confidential Page 2 QSD-010763 Version 4.0 RISK MANAGEMENT PLAN - PART I FINAL DLP:01-JUN-2016 Product Code - Hyoscine butylbromide Version 2.1_CA LIST OF TABLES Table 1 - Product Overview ............................................................................................................................. 5 Property of the Sanofi group - strictly confidential Page 3 QSD-010763 Version 4.0 RISK MANAGEMENT PLAN - PART I FINAL DLP:01-JUN-2016 Product Code - Hyoscine butylbromide Version 2.1_CA ABBREVIATIONS ATC: Anatomical Therapeutic Chemical DLP: Data Lock Point e-CTD: Electronic Common Technical Document EEA: European Economic Area EU: European Union INN: International Nonproprietary Name RMP: Risk Management Plan Property of the Sanofi group - strictly confidential Page 4 QSD-010763 Version 4.0 RISK MANAGEMENT PLAN - PART I FINAL DLP:01-JUN-2016 Product Code - Hyoscine butylbromide Version 2.1_CA Table 1 - Product Overview Active substance(s) Hyoscine butylbromide (INN or common name) Pharmacotherapeutic group(s) Belladonna alkaloids, semisynthetic, quarternary ammonium compounds (ATC Code) (ATC code A03BB01) Marketing Authorization Holder Boehringer Ingelheim
Load more

Recommended publications
  • Distinct Muscarinic Acetylcholine Receptor Subtypes Contribute to Stability and Growth, but Not Compensatory Plasticity, of Neuromuscular Synapses
    14942 • The Journal of Neuroscience, November 25, 2009 • 29(47):14942–14955 Development/Plasticity/Repair Distinct Muscarinic Acetylcholine Receptor Subtypes Contribute to Stability and Growth, But Not Compensatory Plasticity, of Neuromuscular Synapses Megan C. Wright,1 Srilatha Potluri,1 Xueyong Wang,2 Eva Dentcheva,1 Dinesh Gautam,3 Alan Tessler,1,4 Ju¨rgen Wess,3 Mark M. Rich,2 and Young-Jin Son1 1Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania 19129, 2Department of Neuroscience, Cell Biology, and Physiology, Wright State University, Dayton, Ohio 45435, 3Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892, and 4Department of Neurology, Department of Veterans Affairs Hospital, Philadelphia, Pennsylvania 19104 Muscarinic acetylcholine receptors (mAChRs) modulate synaptic function, but whether they influence synaptic structure remains un- known. At neuromuscular junctions (NMJs), mAChRs have been implicated in compensatory sprouting of axon terminals in paralyzed or denervated muscles. Here we used pharmacological and genetic inhibition and localization studies of mAChR subtypes at mouse NMJs to demonstrate their roles in synaptic stability and growth but not in compensatory sprouting. M2 mAChRs were present solely in motor neurons,whereasM1 ,M3 ,andM5 mAChRswereassociatedwithSchwanncellsand/ormusclefibers.BlockadeofallfivemAChRsubtypes with atropine evoked pronounced effects,
    [Show full text]
  • Muscarinic Acetylcholine Type 1 Receptor Activity Constrains Neurite Outgrowth by Inhibiting Microtubule Polymerization and Mito
    fnins-12-00402 June 26, 2018 Time: 12:46 # 1 ORIGINAL RESEARCH published: 26 June 2018 doi: 10.3389/fnins.2018.00402 Muscarinic Acetylcholine Type 1 Receptor Activity Constrains Neurite Outgrowth by Inhibiting Microtubule Polymerization and Mitochondrial Trafficking in Adult Sensory Neurons Mohammad G. Sabbir1*, Nigel A. Calcutt2 and Paul Fernyhough1,3 1 Division of Neurodegenerative Disorders, St. Boniface Hospital Research Centre, Winnipeg, MB, Canada, 2 Department of Pathology, University of California, San Diego, San Diego, CA, United States, 3 Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB, Canada The muscarinic acetylcholine type 1 receptor (M1R) is a metabotropic G protein-coupled Edited by: receptor. Knockout of M1R or exposure to selective or specific receptor antagonists Roberto Di Maio, elevates neurite outgrowth in adult sensory neurons and is therapeutic in diverse University of Pittsburgh, United States models of peripheral neuropathy. We tested the hypothesis that endogenous M1R Reviewed by: activation constrained neurite outgrowth via a negative impact on the cytoskeleton Roland Brandt, University of Osnabrück, Germany and subsequent mitochondrial trafficking. We overexpressed M1R in primary cultures Rick Dobrowsky, of adult rat sensory neurons and cell lines and studied the physiological and The University of Kansas, United States molecular consequences related to regulation of cytoskeletal/mitochondrial dynamics *Correspondence: and neurite outgrowth. In adult primary neurons, overexpression of M1R caused Mohammad G. Sabbir disruption of the tubulin, but not actin, cytoskeleton and significantly reduced neurite [email protected] outgrowth. Over-expression of a M1R-DREADD mutant comparatively increased neurite Specialty section: outgrowth suggesting that acetylcholine released from cultured neurons interacts This article was submitted to with M1R to suppress neurite outgrowth.
    [Show full text]
  • WO 2017/177262 Al 19 October 2017 (19.10.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/177262 Al 19 October 2017 (19.10.2017) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/198 (2006.01) A61P 27/02 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 31/375 (2006.01) A61P 27/10 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/AU20 17/0503 10 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 10 April 2017 (10.04.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 2016901339 11 April 2016 ( 11.04.2016) AU GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: UNIVERSITY OF CANBERRA [AU/AU]; TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, University Drive, Bruce, Australian Capital Territory 2617 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (AU).
    [Show full text]
  • Muscarinic Toxin 7 Signals Via Ca2+/Calmodulin-Dependent Protein Kinase Kinase Β to Augment Mitochondrial Function and Prevent Neurodegeneration
    Molecular Neurobiology (2020) 57:2521–2538 https://doi.org/10.1007/s12035-020-01900-x Muscarinic Toxin 7 Signals Via Ca2+/Calmodulin-Dependent Protein Kinase Kinase β to Augment Mitochondrial Function and Prevent Neurodegeneration Ali Saleh1 & Mohammad Golam Sabbir1 & Mohamad-Reza Aghanoori1,2 & Darrell R. Smith1 & Subir K. Roy Chowdhury1 & Lori Tessler1 & Jennifer Brown1 & Eva Gedarevich3 & Markos Z. Kassahun3 & Katie Frizzi3 & Nigel A. Calcutt 3 & Paul Fernyhough1,2 Received: 9 January 2020 /Accepted: 9 March 2020 /Published online: 20 March 2020 # The Author(s) 2020 Abstract Mitochondrial dysfunction is implicated in a variety of neurodegenerative diseases of the nervous system. Peroxisome proliferator–activated receptor-γ coactivator-1α (PGC-1α) is a regulator of mitochondrial function in multiple cell types. In sensory neurons, AMP-activated protein kinase (AMPK) augments PGC-1α activity and this pathway is depressed in diabetes leading to mitochondrial dysfunction and neurodegeneration. Antimuscarinic drugs targeting the muscarinic acetylcholine type 1 receptor (M1R) prevent/reverse neurodegeneration by inducing nerve regeneration in rodent models of diabetes and chemotherapy-induced peripheral neuropathy (CIPN). Ca2+/calmodulin-dependent protein kinase kinase β (CaMKKβ)isan upstream regulator of AMPK activity. We hypothesized that antimuscarinic drugs modulate CaMKKβ to enhance activity of AMPK, and PGC-1α, increase mitochondrial function and thus protect from neurodegeneration. We used the specific M1R antagonist muscarinic toxin 7 (MT7) to manipulate muscarinic signaling in the dorsal root ganglia (DRG) neurons of normal rats or rats with streptozotocin-induced diabetes. DRG neurons treated with MT7 (100 nM) or a selective muscarinic antagonist, pirenzepine (1 μM), for 24 h showed increased neurite outgrowth that was blocked by the CaMKK inhibitor STO-609 (1 μM) or short hairpin RNA to CaMKKβ.
    [Show full text]
  • 1: Gastro-Intestinal System
    1 1: GASTRO-INTESTINAL SYSTEM Antacids .......................................................... 1 Stimulant laxatives ...................................46 Compound alginate products .................. 3 Docuate sodium .......................................49 Simeticone ................................................... 4 Lactulose ....................................................50 Antimuscarinics .......................................... 5 Macrogols (polyethylene glycols) ..........51 Glycopyrronium .......................................13 Magnesium salts ........................................53 Hyoscine butylbromide ...........................16 Rectal products for constipation ..........55 Hyoscine hydrobromide .........................19 Products for haemorrhoids .................56 Propantheline ............................................21 Pancreatin ...................................................58 Orphenadrine ...........................................23 Prokinetics ..................................................24 Quick Clinical Guides: H2-receptor antagonists .......................27 Death rattle (noisy rattling breathing) 12 Proton pump inhibitors ........................30 Opioid-induced constipation .................42 Loperamide ................................................35 Bowel management in paraplegia Laxatives ......................................................38 and tetraplegia .....................................44 Ispaghula (Psyllium husk) ........................45 ANTACIDS Indications:
    [Show full text]
  • Venom Week 2012 4Th International Scientific Symposium on All Things Venomous
    17th World Congress of the International Society on Toxinology Animal, Plant and Microbial Toxins & Venom Week 2012 4th International Scientific Symposium on All Things Venomous Honolulu, Hawaii, USA, July 8 – 13, 2012 1 Table of Contents Section Page Introduction 01 Scientific Organizing Committee 02 Local Organizing Committee / Sponsors / Co-Chairs 02 Welcome Messages 04 Governor’s Proclamation 08 Meeting Program 10 Sunday 13 Monday 15 Tuesday 20 Wednesday 26 Thursday 30 Friday 36 Poster Session I 41 Poster Session II 47 Supplemental program material 54 Additional Abstracts (#298 – #344) 61 International Society on Thrombosis & Haemostasis 99 2 Introduction Welcome to the 17th World Congress of the International Society on Toxinology (IST), held jointly with Venom Week 2012, 4th International Scientific Symposium on All Things Venomous, in Honolulu, Hawaii, USA, July 8 – 13, 2012. This is a supplement to the special issue of Toxicon. It contains the abstracts that were submitted too late for inclusion there, as well as a complete program agenda of the meeting, as well as other materials. At the time of this printing, we had 344 scientific abstracts scheduled for presentation and over 300 attendees from all over the planet. The World Congress of IST is held every three years, most recently in Recife, Brazil in March 2009. The IST World Congress is the primary international meeting bringing together scientists and physicians from around the world to discuss the most recent advances in the structure and function of natural toxins occurring in venomous animals, plants, or microorganisms, in medical, public health, and policy approaches to prevent or treat envenomations, and in the development of new toxin-derived drugs.
    [Show full text]
  • Fluticasone Furoate and Vilanterol for the Treatment of Chronic Obstructive Pulmonary Disease
    Expert Review of Respiratory Medicine ISSN: 1747-6348 (Print) 1747-6356 (Online) Journal homepage: http://www.tandfonline.com/loi/ierx20 Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease Gaetano Caramori, Paolo Ruggeri, Paolo Casolari, Kian Fan Chung, Giuseppe Girbino & Ian M. Adcock To cite this article: Gaetano Caramori, Paolo Ruggeri, Paolo Casolari, Kian Fan Chung, Giuseppe Girbino & Ian M. Adcock (2017): Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease, Expert Review of Respiratory Medicine, DOI: 10.1080/17476348.2017.1386564 To link to this article: http://dx.doi.org/10.1080/17476348.2017.1386564 Accepted author version posted online: 28 Sep 2017. Submit your article to this journal View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ierx20 Download by: [Imperial College London Library] Date: 29 September 2017, At: 01:13 Publisher: Taylor & Francis Journal: Expert Review of Respiratory Medicine DOI: 10.1080/17476348.2017.1386564 Review Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease Gaetano Caramori1*, Paolo Ruggeri1, Paolo Casolari2, Kian Fan Chung3, Giuseppe Girbino1, Ian M. Adcock3. 1Unità Operativa Complessa di Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF) Università degli Studi di Messina, Italy. 2Centro Interdipartimentale per lo Studio delle Malattie Infiammatorie delle Vie Aeree e Patologie Fumo-correlate (CEMICEF; formerly Centro di Ricerca su Asma e BPCO), Sezione di Medicina Interna e Cardiorespiratoria, Università di Ferrara, Ferrara, Italy. 3Airways Disease Section, National Heart and Lung Institute, Royal Brompton Hospital Biomedical Research Unit, Imperial College London, UK.
    [Show full text]
  • Oregon Drug Use Review / Pharmacy & Therapeutics Committee
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Oregon Drug Use Review / Pharmacy & Therapeutics Committee Thursday, January 25, 2018 1:00 - 5:00 PM Barbara Roberts Human Services Building 500 Summer St. NE Salem, OR 97301 MEETING AGENDA NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9). I. CALL TO ORDER 1:00 PM A. Roll Call & Introductions R. Citron (OSU) B. Roles and Responsibilities of Committee Members T. Douglass (OHA) C. Conflict of Interest Declaration R. Citron (OSU) D. Election of Chair & Vice Chair R. Citron (OSU) E. Department and Legislative Update T. Douglass (OHA) F. Approval of Agenda and Minutes II. CONSENT AGENDA TOPICS R. Citron (OSU) 1:25 PM A. Noctiva® (desmopressin) Abbreviated Drug Review B. Drugs for Asthma and COPD Literature Scan 1. Public Comment III. DUR NEW BUSINESS 1:30 PM A. Hepatitis C Direct-Acting Antivirals Policy Discussion R. Citron (OSU) 1. Prior Authorization Criteria A. Seaman (OHSU) 2. Treatment of Hepatitis C in People who Inject Drugs 3.
    [Show full text]
  • Muscarinic, Adenosine and Tropomyosin-Related Kinase B Receptor Modulate the Neuromuscular Developmental Synapse Elimination Process
    Muscarinic, adenosine and tropomyosin-related kinase B receptor modulate the neuromuscular developmental synapse elimination process Laura Nadal Magriñà ADVERTIMENT. L'accés als continguts d'aquesta tesi doctoral i la seva utilització ha de respectar els drets de la persona autora. Pot ser utilitzada per a consulta o estudi personal, així com en activitats o materials d'investigació i docència en els termes establerts a l'art. 32 del Text Refós de la Llei de Propietat Intel·lectual (RDL 1/1996). Per altres utilitzacions es requereix l'autorització prèvia i expressa de la persona autora. En qualsevol cas, en la utilització dels seus continguts caldrà indicar de forma clara el nom i cognoms de la persona autora i el títol de la tesi doctoral. No s'autoritza la seva reproducció o altres formes d'explotació efectuades amb finalitats de lucre ni la seva comunicació pública des d'un lloc aliè al servei TDX. Tampoc s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant als continguts de la tesi com als seus resums i índexs. ADVERTENCIA. El acceso a los contenidos de esta tesis doctoral y su utilización debe respetar los derechos de la persona autora. Puede ser utilizada para consulta o estudio personal, así como en actividades o materiales de investigación y docencia en los términos establecidos en el art. 32 del Texto Refundido de la Ley de Propiedad Intelectual (RDL 1/1996). Para otros usos se requiere la autorización previa y expresa de la persona autora. En cualquier caso, en la utilización de sus contenidos se deberá indicar de forma clara el nombre y apellidos de la persona autora y el título de la tesis doctoral.
    [Show full text]
  • Association of Pain with Muscarinic Receptors
    wjpmr, 2018,4(5), 286-295 SJIF Impact Factor: 4.639 WORLD JOURNAL OF PHARMACEUTICAL Research Article Asif et al. AND MEDICAL RESEARCH World Journal of Pharmaceutical and Medical ResearchISSN 2455 -3301 www.wjpmr.com WJPMR ASSOCIATION OF PAIN WITH MUSCARINIC RECEPTORS Dr. Asif Ali*1, Dr. Samia Saba Hamdani2 and Dr. Kiran Shahzadi3 1PMDC # : 85094-P. 2PMDC # : 82129-P. 3PMDC # : 82517-P. *Corresponding Author: Dr. Asif Ali PMDC # : 85094-P. Article Received on 19/03/2018 Article Revised on 09/04/2018 Article Accepted on 30/04/2018 ABSTRACT Pain is an unpleasant experience comes along with any kind of damage and effects daily routine negatively. Although there are various drugs, many of them could not completely succeed in relieving pain due to pain modulation is a complex process involving numerous mediators and receptors. Therefore, it is a rational approach to identifying the components involved in this complex process and develop new agents act on these components. In this respect, the involvement of muscarinic receptors in pain modulation has drawn attention in recent years. The aim of the review is to exhibit the involvement of the muscarinic receptor subtypes that contribute to pain modulation. The search strategy was performed with MeSH terms and free text words, using the bibliographic databases Science Direct and PubMed. The articles have been collected from the experimental animal studies. It is obvious that muscarinic receptors that are located in both peripheral and central areas are extensively involved in the pain process, besides the regional effectiveness of these receptors and their subtypes may vary. Since the muscarinic receptors are various and involve in many physiologic processes, the possibility of adverse effects is a problem in their clinical use.
    [Show full text]
  • Pharmacology and Therapeutics of Bronchodilators
    1521-0081/12/6403-450–504$25.00 PHARMACOLOGICAL REVIEWS Vol. 64, No. 3 Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics 4580/3762238 Pharmacol Rev 64:450–504, 2012 ASSOCIATE EDITOR: DAVID R. SIBLEY Pharmacology and Therapeutics of Bronchodilators Mario Cazzola, Clive P. Page, Luigino Calzetta, and M. Gabriella Matera Department of Internal Medicine, Unit of Respiratory Clinical Pharmacology, University of Rome ‘Tor Vergata,’ Rome, Italy (M.C., L.C.); Department of Pulmonary Rehabilitation, San Raffaele Pisana Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy (M.C., L.C.); Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UK (C.P.P., L.C.); and Department of Experimental Medicine, Unit of Pharmacology, Second University of Naples, Naples, Italy (M.G.M.) Abstract............................................................................... 451 I. Introduction: the physiological rationale for using bronchodilators .......................... 452 II. ␤-Adrenergic receptor agonists .......................................................... 455 A. A history of the development of ␤-adrenergic receptor agonists: from nonselective ␤ Downloaded from adrenergic receptor agonists to 2-adrenergic receptor-selective drugs.................... 455 ␤ B. Short-acting 2-adrenergic receptor agonists........................................... 457 1. Albuterol........................................................................ 457
    [Show full text]
  • Different Roles for M1 and M2 Receptors Within Perirhinal Cortex in Object Recognition and Discrimination ⇑ Susan J
    Neurobiology of Learning and Memory 110 (2014) 16–26 Contents lists available at ScienceDirect Neurobiology of Learning and Memory journal homepage: www.elsevier.com/locate/ynlme Different roles for M1 and M2 receptors within perirhinal cortex in object recognition and discrimination ⇑ Susan J. Bartko a,b, , Boyer D. Winters c, Lisa M. Saksida a,b, Timothy J. Bussey a,b a Department of Experimental Psychology, University of Cambridge, Downing St., Cambridge CB2 3EB, UK b MRC and Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge CB2 3EB, UK c Department of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, Ontario N1G 2W1, Canada article info abstract Article history: Recognition and discrimination of objects and individuals are critical cognitive faculties in both humans Received 11 September 2013 and non-human animals, and cholinergic transmission has been shown to be essential for both of these Revised 30 December 2013 functions. In the present study we focused on the role of M1 and M2 muscarinic receptors in perirhinal Accepted 6 January 2014 cortex (PRh)-dependent object recognition and discrimination. The selective M antagonists pirenzepine Available online 24 January 2014 1 and the snake toxin MT-7, and a selective M2 antagonist, AF-DX 116, were infused directly into PRh. Pre-sample infusions of both pirenzepine and AF-DX 116 significantly impaired object recognition mem- Keywords: ory in a delay-dependent manner. However, pirenzepine and MT-7, but not AF-DX 116, impaired oddity Medial temporal lobe discrimination performance in a perceptual difficulty-dependent manner. The findings indicate distinct Pirenzepine AF-DX 116 functions for M1 and M2 receptors in object recognition and discrimination.
    [Show full text]